Overview

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Subjects will have painful primary or post-operative intermetatarsal neuroma. Study drug or placebo will be injected into the space containing the neuroma. Subjects will complete weekly assessments for severity of foot pain, a brief pain inventory, and the amount of pain medication taken. Subjects will be seen for a screening visit, a treatment visit, and two follow-up visits after treatment. The last scheduled visit is one month after treatment. Some subjects may be followed by monthly telephone interviews to assess their level of pain over the six-month period following treatment.
Phase:
Phase 2
Details
Lead Sponsor:
AlgoRx Pharmaceuticals